71 related articles for article (PubMed ID: 9334150)
21. Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma.
Linder S; Castaños-Velez E; von Rosen A; Biberfeld P
Hepatogastroenterology; 2001; 48(41):1321-7. PubMed ID: 11677955
[TBL] [Abstract][Full Text] [Related]
22. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
Malamou-Mitsi VD; Syrrou M; Georgiou I; Pagoulatos G; Agnantis NJ
J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
[TBL] [Abstract][Full Text] [Related]
23. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
Naidu R; Wahab NA; Yadav M; Kutty MK
Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
[TBL] [Abstract][Full Text] [Related]
24. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
[TBL] [Abstract][Full Text] [Related]
25. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas.
Zhang GJ; Kimijima I; Abe R; Kanno M; Katagata N; Hara K; Watanabe T; Tsuchiya A
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2329-35. PubMed ID: 9815631
[TBL] [Abstract][Full Text] [Related]
26. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
Erdogan S; Ergin M; Tuncer I
Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
[TBL] [Abstract][Full Text] [Related]
27. Expression of the c-erbB-2 gene product as detected in cytologic aspirates in breast cancer.
Allan SM; Fernando IN; Sandle J; Trott PA
Acta Cytol; 1993; 37(6):981-2. PubMed ID: 7902634
[No Abstract] [Full Text] [Related]
28. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.
Tsanou E; Ioachim E; Briasoulis E; Charchanti A; Damala K; Karavasilis V; Pavlidis N; Agnantis NJ
J Exp Clin Cancer Res; 2004 Dec; 23(4):641-50. PubMed ID: 15743035
[TBL] [Abstract][Full Text] [Related]
29. Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4.
Tiniakos DG; Scott LE; Corbett IP; Piggott NH; Horne CH
J Pathol; 1994 Jan; 172(1):19-26. PubMed ID: 7931823
[TBL] [Abstract][Full Text] [Related]
30. Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas.
Suo Z; Su W; Holm R; Nesland JM
Anticancer Res; 1995; 15(6B):2797-8. PubMed ID: 8669867
[TBL] [Abstract][Full Text] [Related]
31. Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade.
Tsuda H; Fukutomi T; Hirohashi S
Clin Cancer Res; 1995 Mar; 1(3):261-7. PubMed ID: 9815981
[TBL] [Abstract][Full Text] [Related]
32. Loss of types XV and XIX collagen precedes basement membrane invasion in ductal carcinoma of the female breast.
Amenta PS; Hadad S; Lee MT; Barnard N; Li D; Myers JC
J Pathol; 2003 Mar; 199(3):298-308. PubMed ID: 12579531
[TBL] [Abstract][Full Text] [Related]
33. Integrin expression on normal and neoplastic human breast epithelium.
Damjanovich L; Fülöp B; Adány R; Nemes Z
Acta Chir Hung; 1997; 36(1-4):69-71. PubMed ID: 9408292
[TBL] [Abstract][Full Text] [Related]
34. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
35. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
Sirotkovic-Skerlev M; Krizanac S; Kapitanovic S; Husnjak K; Unusic J; Pavelic K
Exp Mol Pathol; 2005 Aug; 79(1):42-50. PubMed ID: 16005711
[TBL] [Abstract][Full Text] [Related]
36. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
37. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
[TBL] [Abstract][Full Text] [Related]
38. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
39. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
40. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
